{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:34:07Z","timestamp":1792852447664,"version":"4.5.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swiss National Research Foundation","award":["320030-120686, 324730-144064, 320030-173211, 320030-200602"],"award-info":[{"award-number":["320030-120686, 324730-144064, 320030-173211, 320030-200602"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) is strongly recommended for olanzapine due to its high pharmacokinetic variability. This study aimed to investigate the impact of various clinical factors on olanzapine plasma concentrations in patients with psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study used TDM data from the PsyMetab cohort, including 547 daily dose\u2013normalized, steady-state, olanzapine plasma concentrations (C:D ratios) from 248 patients. Both intrinsic factors (eg, sex, age, body weight) and extrinsic factors (eg, smoking status, comedications, hospitalization) were examined. Univariate and multivariable, linear, mixed-effects models were employed, with a stepwise selection procedure based on Akaike information criterion to identify the relevant covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the multivariable model (based on 440 observations with a complete data set), several significant findings emerged. Olanzapine C:D ratios were significantly lower in smokers (\u03b2 = \u22120.65,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), valproate users (\u03b2 = \u22120.53,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and inpatients (\u03b2 = \u22120.20,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.025). Furthermore, the C:D ratios decreased significantly as the time since the last dose increased (\u03b2 = \u22120.040,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The male sex had a significant main effect on olanzapine C:D ratios (\u03b2 = \u22122.80,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), with significant interactions with age (\u03b2 = 0.025,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and body weight (\u03b2 = 0.017,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011). The selected covariates explained 30.3% of the variation in C:D ratios, with smoking status accounting for 7.7% and sex contributing 6.9%. The overall variation explained by both the fixed and random parts of the model was 67.4%. The model facilitated the prediction of olanzapine C:D ratios based on sex, age, and body weight.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The clinical factors examined in this study, including sex, age, body weight, smoking status, and valproate comedication, remarkably influence olanzapine C:D ratios. Considering these factors, in addition to TDM and the clinical situation, could be important for dose adjustment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001227","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:46:05Z","timestamp":1717523165000},"page":"828-836","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-9416","authenticated-orcid":false,"given":"Nicolas","family":"Ansermot","sequence":"first","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Vathanarasa","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Ranjbar","sequence":"additional","affiliation":[{"name":"Psychiatric Epidemiology and Psychopathology Research Centre, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Gholam","sequence":"additional","affiliation":[{"name":"Psychiatric Epidemiology and Psychopathology Research Centre, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Crettol","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Gamma","sequence":"additional","affiliation":[{"name":"Les Toises Psychiatry and Psychotherapy Centre, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Jessica","family":"Plessen","sequence":"additional","affiliation":[{"name":"Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[{"name":"Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[{"name":"Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[{"name":"Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland;"},{"name":"Centre for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland;"},{"name":"School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; and"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva and Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14740330802423234","article-title":"Olanzapine: review of safety 2008","volume":"7","author":"Kantrowitz","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine: an updated review of its use in the management of schizophrenia","volume":"61","author":"Bhana","year":"2001","journal-title":"Drugs"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/pgs.13.120","article-title":"Pharmacogenetics of olanzapine metabolism","volume":"14","author":"S\u00f6derberg","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1124\/dmd.115.064790","article-title":"In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism","volume":"43","author":"Korprasertthaworn","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00498254.2022.2078751","article-title":"Metabolism of the antipsychotic drug olanzapine by CYP3A43","volume":"52","author":"Zhao","year":"2022","journal-title":"Xenobiotica"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"Skogh","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e0148539","DOI":"10.1371\/journal.pone.0148539","article-title":"Application of plasma levels of olanzapine and N-Desmethyl-Olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"22r14626","DOI":"10.4088\/JCP.22r14626","article-title":"Therapeutic reference range for olanzapine in schizophrenia: systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy","volume":"84","author":"Wesner","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/JCP.0000000000001618","article-title":"Effects of age, sex, and comedication on the plasma concentrations of olanzapine in Chinese patients with schizophrenia based on therapeutic drug monitoring data","volume":"42","author":"Ding","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JCP.0000000000000961","article-title":"Age impacts olanzapine exposure differently during use of oral versus long-acting injectable formulations: an observational study including 8,288 patients","volume":"38","author":"Tveito","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3182693d2a","article-title":"Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking","volume":"34","author":"Haslemo","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JCP.0000000000001390","article-title":"Effects of dose, age, sex, body weight, and smoking on plasma concentrations of olanzapine and N-desmethyl olanzapine in inpatients with schizophrenia","volume":"41","author":"An","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FTD.0b013e3181c0590e","article-title":"Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder","volume":"31","author":"Spina","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine","volume":"62","author":"Haslemo","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815527","article-title":"Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients","volume":"37","author":"Bergemann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cpt.2412","article-title":"Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail","volume":"110","author":"Lenoir","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment","volume":"76","author":"Vandenberghe","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/FTD.0000000000000738","article-title":"A retrospective analysis of steady-state olanzapine concentrations in Chinese patients using therapeutic drug monitoring: effects of valproate and other factors","volume":"42","author":"Deng","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cpt.1949","article-title":"Effect of high-dose esomeprazole on CYP1A2, CYP2C19, and CYP3A4 activities in humans: evidence for substantial and long-lasting inhibition of CYP2C19","volume":"108","author":"Kaartinen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/00912709922008560","article-title":"Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women","volume":"39","author":"Pollock","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.chroma.2012.12.071","article-title":"Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring","volume":"1292","author":"Ansermot","year":"2013","journal-title":"J Chromatogr A"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13318-021-00673-5","article-title":"The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients","volume":"46","author":"Zang","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/clpt.2011.70","article-title":"Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility","volume":"90","author":"Dobrinas","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","article-title":"Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine","volume":"276","author":"Ring","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/ph14060514","article-title":"Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics","volume":"14","author":"Moschny","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/17425255.4.4.413","article-title":"Sex-specific differences in CYP450 isoforms in humans","volume":"4","author":"Scandlyn","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1176\/ajp.149.5.587","article-title":"Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication","volume":"149","author":"Yonkers","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs","volume":"161","author":"Seeman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0193-953X(05)70401-9","article-title":"Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology","volume":"20","author":"Catterson","year":"1997","journal-title":"Psychiatr Clin North Am"},{"key":"R46-20250603","first-page":"235","article-title":"Gender differences in psychotropic drug metabolism","volume":"33","author":"Pollock","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5493\/wjem.v13.i3.7","article-title":"Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus","volume":"13","author":"Lempesis","year":"2023","journal-title":"World J Exp Med"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1111\/bcp.15349","article-title":"Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity","volume":"88","author":"Kvitne","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"20405","DOI":"10.1038\/s41598-019-57002-9","article-title":"Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity","volume":"9","author":"Rodr\u00edguez-Morat\u00f3","year":"2019","journal-title":"Sci Rep"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0000000000001126","article-title":"The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections","volume":"39","author":"Tveito","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/bcp.13646","article-title":"Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy","volume":"84","author":"Klarica Domjanovi\u0107","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1208\/ps040209","article-title":"Influence of fluoxetine on olanzapine pharmacokinetics","volume":"4","author":"Gossen","year":"2002","journal-title":"AAPS PharmSci"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"531763","DOI":"10.3389\/fnins.2020.531763","article-title":"Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis","volume":"14","author":"El Abdellati","year":"2020","journal-title":"Front Neurosci"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/a-0869-8053","article-title":"Pathological concentration of C-reactive protein is correlated to increased concentrations of quetiapine, but not of risperidone, olanzapine and aripiprazole in a naturalistic setting","volume":"53","author":"Scherf-Clavel","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1055-9965.EPI-09-0589","article-title":"CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial","volume":"18","author":"Peterson","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0960-894X(96)00567-7","article-title":"The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)","volume":"7","author":"Calligaro","year":"1997","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:12:42Z","timestamp":1748956362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001227","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"2024-01-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}